Peter T Dziegielewski1,2,3, Margaret L McNeely4, Nigel Ashworth5, Daniel A O'Connell3, Brittany Barber3, Kerry S Courneya6, Brock J Debenham7, Hadi Seikaly3. 1. Department of Otolaryngology, University of Florida, Gainesville, Florida. 2. University of Florida Health Cancer Center, University of Florida, Gainesville, Florida. 3. Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada. 4. Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, Alberta, Canada. 5. Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. 6. Faculty of Physical Education and Recreation, University of Alberta, Edmonton, Alberta, Canada. 7. Department of Radiation Oncology, University of Alberta, Edmonton, Alberta, Canada.
Abstract
BACKGROUND:Selective neck dissection (SND) is a mainstay of head and neck cancer treatment. A common sequela is shoulder syndrome from spinal accessory nerve (SAN) trauma. Extensive dissection in neck levels 2 and 5 leads to SAN dysfunction. However, it is not known whether limited level 2 dissection reduces SAN injury. The purpose of this double-blind randomized controlled trial was to determine whether omitting level 2b dissection would improve shoulder-related quality of life and function. METHODS:Patients with head and neck cancers undergoing surgery were randomized 1:1 to SND without level 2b dissection (group 1) or with it (group 2) on their dominant-hand side. Patients, caregivers, and assessors were blinded. The primary outcome was the change in the Neck Dissection Impairment Index (NDII) score after 6 months. An a priori calculation of the minimally important clinical difference in the NDII score was determined to establish a sample size of 15 patients per group (power = 0.8). Secondary outcomes included shoulder strength and range of motion (ROM) and SAN nerve conduction. The trial was registered at ClinicalTrials.gov (NCT00765791). RESULTS:Forty patients were enrolled, and 30 were included (15 per group). Six months after the surgery, group 2 demonstrated a significant median decrease in the NDII from the baseline (30 points) and in comparison with group 1, whose NDII dropped 17.5 points (P = .02). Shoulder ROM and SAN conduction demonstrated significant declines in group 2 (P ≤ .05). No adverse events occurred. CONCLUSIONS: Level 2b should be omitted in SND when this is oncologically safe and feasible. This allows for an optimal balance between function and cancer cure.
RCT Entities:
BACKGROUND: Selective neck dissection (SND) is a mainstay of head and neck cancer treatment. A common sequela is shoulder syndrome from spinal accessory nerve (SAN) trauma. Extensive dissection in neck levels 2 and 5 leads to SAN dysfunction. However, it is not known whether limited level 2 dissection reduces SAN injury. The purpose of this double-blind randomized controlled trial was to determine whether omitting level 2b dissection would improve shoulder-related quality of life and function. METHODS:Patients with head and neck cancers undergoing surgery were randomized 1:1 to SND without level 2b dissection (group 1) or with it (group 2) on their dominant-hand side. Patients, caregivers, and assessors were blinded. The primary outcome was the change in the Neck Dissection Impairment Index (NDII) score after 6 months. An a priori calculation of the minimally important clinical difference in the NDII score was determined to establish a sample size of 15 patients per group (power = 0.8). Secondary outcomes included shoulder strength and range of motion (ROM) and SAN nerve conduction. The trial was registered at ClinicalTrials.gov (NCT00765791). RESULTS: Forty patients were enrolled, and 30 were included (15 per group). Six months after the surgery, group 2 demonstrated a significant median decrease in the NDII from the baseline (30 points) and in comparison with group 1, whose NDII dropped 17.5 points (P = .02). Shoulder ROM and SAN conduction demonstrated significant declines in group 2 (P ≤ .05). No adverse events occurred. CONCLUSIONS: Level 2b should be omitted in SND when this is oncologically safe and feasible. This allows for an optimal balance between function and cancer cure.
Authors: Sara C Parke; David Michael Langelier; Jessica Tse Cheng; Cristina Kline-Quiroz; Michael Dean Stubblefield Journal: Curr Oncol Rep Date: 2022-02-19 Impact factor: 5.075
Authors: Susanne I Scott; Anne Kathrine Ø Madsen; Niclas Rubek; Birgitte W Charabi; Irene Wessel; Sara Fredslund Hadjú; Claus V Jensen; Sarah Stephen; Joanne M Patterson; Jeppe Friborg; Kathrine A Hutcheson; Henrik Kehlet; Christian von Buchwald Journal: Cancer Med Date: 2020-12-04 Impact factor: 4.452
Authors: Arne Böttcher; Christian S Betz; Stefan Bartels; Bjoern Schoennagel; Adrian Münscher; Lara Bußmann; Chia-Jung Busch; Steffen Knopke; Eric Bibiza; Nikolaus Möckelmann Journal: J Cancer Res Clin Oncol Date: 2020-08-18 Impact factor: 4.553